Food News and Research

RSS

Pairing adolescents with college student mentors keeps kids healthy, fit

A program pairing healthy young adults with urban middle school students helped the adolescents adopt healthy habits, active lifestyles and a healthy weight, according to a new study from the University of Maryland School of Medicine. The study, published August 2 in the journal Pediatrics, found that linking African American, inner city adolescents in Baltimore with one-on-one mentorship from college students prevented the schoolchildren from becoming overweight for at least two years after the mentorship experience. Researchers found the adolescents ate fewer snacks and desserts, and engaged in active play more often. The rate of overweight/obesity in the group declined five percent.

3 Aug 2010

Study finds hunger as a serious risk factor for long-term poor health among children, youth

Children and youth who experience hunger appear more likely to have health problems, and repeated episodes of hunger may be particularly toxic, according to a report in the August issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

3 Aug 2010

Antisense Pharma receives FDA IND authorisation for clinical studies with trabedersen for high-grade glioma

The biopharmaceutical company Antisense Pharma announced today that the US-American Food and Drug Administration (FDA) has issued an Investigational New Drug (IND)-authorisation for clinical studies with trabedersen for patients with high-grade glioma. This authorisation entitles the company to include US-American clinics both in the phase III study SAPPHIRE and in further studies.

3 Aug 2010

ArQule, Daiichi Sankyo announce decision to advance ARQ 197 into Phase 3 clinical trial for NSCLC

ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced that they will move forward with a Phase 3 clinical trial of ARQ 197, a small molecule inhibitor of the c-Met receptor tyrosine kinase, in patients with non-small cell lung cancer (NSCLC). In connection with this decision, the sponsor company, Daiichi Sankyo, will file a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) for a trial comparing ARQ 197 plus erlotinib against erlotinib plus placebo.

3 Aug 2010

FDA approves N30 Pharma's NDA for N6022 GSNOR

N30 Pharmaceuticals, LLC today announced the approval of its Investigational New Drug Application for N6022 by the U.S. Food and Drug Administration. N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR), has the potential to be an important new treatment for acute exacerbations of asthma, chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD).

3 Aug 2010

VIVUS second-quarter total revenue decreases to $3.9 million

VIVUS, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its financial results for the second quarter and six months ended June 30, 2010.

3 Aug 2010

Environmental influences on college freshman weight gain

If college students gain weight during their first year in school, it might have a lot to do with how close they live to their campus dining halls and exercise facilities, a new study reports.

3 Aug 2010

World Breastfeeding Week highlights benefits to infant, child nutrition, health

Kicking off World Breastfeeding Week Sunday, the WHO together with UNICEF emphasized the importance of the agencies' 10 steps to successful breastfeeding to improve health of infants and children around the world, VOA News reports (Schlein, 8/1).

3 Aug 2010

Percutaneous heart valve replacement may be an alternative for open heart surgery

A newer, less invasive method of heart valve replacement shows promise and may be appropriate for patients who cannot tolerate traditional open heart surgery, but research is needed to understand its potential risks and benefits, according to a new study funded by HHS' Agency for Healthcare Research and Quality.

3 Aug 2010

Allergan second-quarter diluted EPS increases to $0.78

Allergan, Inc. today announced operating results for the quarter ended June 30, 2010. Allergan also announced that its Board of Directors has declared a second quarter dividend of $0.05 per share, payable on September 7, 2010 to stockholders of record on August 17, 2010.

3 Aug 2010

Pakistani officials fear cholera outbreak after massive flooding

After floods in northwest Pakistan have "already killed up to 1,200 people" and forced 2 million from their homes, authorities are now concerned about disease spread, the Associated Press reports.

2 Aug 2010

Octapharma USA receives confirmation of orphan drug exclusivity from FDA for wilate

Octapharma USA has received confirmation of orphan drug exclusivity from the U.S. Food and Drug Administration for wilate (von Willebrand Factor/Factor VIII Concentrate, Human), the replacement therapy developed specifically for von Willebrand Disease. The approval comes from the FDA Office of Orphan Products Development, which helps to advance the development of products that demonstrate promise for the treatment of rare diseases.

2 Aug 2010

WellDoc DiabetesManager System receives FDA clearance

WellDoc, a healthcare company that develops technology solutions to improve chronic disease management outcomes and reduce healthcare costs, today announced that it has received United States Food and Drug Administration 510(k) clearance to market the WellDoc DiabetesManager System to healthcare providers and their adult patients with type 2 diabetes.

2 Aug 2010

Xeomin receives FDA approval for treatment of cervical dystonia

Merz Pharmaceuticals today announced that the United States Food and Drug Administration has approved Xeomin (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm. According to an epidemiology study conducted in Rochester, Minnesota, the prevalence of focal dystonia, which includes cervical dystonia and blepharospasm, is estimated at 295 per million people in the U.S.

2 Aug 2010

Life Technologies launches new assay to detect deadly strain of E. coli

Life Technologies, a provider of innovative life science solutions, announced at the International Association of Food Protection annual meeting the launch of the MicroSEQ E. coli O157:H7 assay, designed to detect the deadly strain of Escherichia coli (E. coli), using the company's industry-leading real-time PCR technology.

2 Aug 2010

Nutritional labeling, point-of-purchase signs influence healthy food choices: Study

Poor diet and physical inactivity leading to obesity are poised to overtake tobacco use as the leading cause of preventable death in the United States. With over 30% of U.S. adults obese, the significant adverse health effects of obesity (including heart disease and diabetes) are widespread throughout the country. Two studies published in the August issue of the Journal of the American Dietetic Association shed light on behaviors regarding food choices and good nutrition and report on how nutritional labeling and point-of-purchase signs are influencing healthy food choices.

2 Aug 2010

Merck reports strong bottom-line performance in second quarter

Merck & Co., Inc. today announced financial results for the second quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the second quarter of $0.86, which excludes purchase accounting adjustments, merger-related expenses, restructuring costs and the gain on AstraZeneca's asset option exercise. Second-quarter GAAP EPS was $0.24.

2 Aug 2010

First regional student food drive to fight hunger

High schools throughout Southeastern Pennsylvania are invited to join Shire's The Great Food Fight!, the first regional student food drive to fight hunger. The goal: to collect 25 tons of food - the equivalent of 50,000 meals - for Philabundance and the thousands of local families who rely on the food services they provide. Shire will present the school that collects the most food per student a grand prize of $10,000.

31 Jul 2010

Nathan Heron teams up with Healthy and Essential to launch Omega Ice Cream

Local ice cream entrepreneur Nathan Heron's popular ice cream concession on Blackpool's famous South Pier will see the launch of a world first - Omega Ice Creams. 'Blackpool is the world's No.1 ice cream eating city.' says Nathan, 'And I love coming up with new ideas - and making a great summer treat like an ice cream healthier with a squeeze of Omega-3 sauce is a great idea!'

31 Jul 2010

Perrigo files ANDA for butoconazole nitrate vaginal cream

Perrigo Company announced that it has filed with the U.S. Food and Drug Administration an Abbreviated New Drug Application for butoconazole nitrate vaginal cream, 2% and that is has notified KV Pharmaceutical Company, the owner of the New Drug Application as well as FemmePharma, the listed owner of the patent, of its ANDA filing. KV is a licensee under the patent. Perrigo believes it is first-to-file on this product.

31 Jul 2010